CONDUIT PHARMACEUTICALS INC (CDT) Stock News
NASDAQ:CDT - Nasdaq - US20678X2053 - Common Stock - Currency: USD
CDT Latest News, Press Relases and Analysis
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market ...
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance ...
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split...
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Announces Leadership Changes...
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program...
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel...
Conduit Pharma Stock Drops On Reverse Stock Split Announcement: Retail’s Pessimistic
The company said that the reverse stock split will become effective on May 19 at 5:00 p.m. ET, and the stock will start trading on a reverse stock-split adjusted basis at market open on May 20.
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases...
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model...
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset...
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Conduit Pharmaceuticals Announces Leadership Changes
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects...
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization...
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases...
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904...
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
Conduit Progresses Phase II of its AI Initiative with Sarborg
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model